Emcure Pharmaceuticals Ltd (EMCU)

Currency in INR
1,998.70
+3.50(+0.18%)
Closed·
Advertisement
EMCU is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1,985.002,024.90
52 wk Range
1,260.002,048.00
Key Statistics
Bid/Ask
1,998.70 / 2,000.00
Prev. Close
1,995.2
Open
1,995.2
Day's Range
1,985-2,024.9
52 wk Range
1,260-2,048
Volume
97.59K
Average Volume (3m)
178.9K
1-Year Change
43.8017%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EMCU Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2,214.29
Upside
+10.79%
Members' Sentiments
Bearish
Bullish
ProTips
Stock price often moves in the opposite direction of the market

Emcure Pharmaceuticals Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Analyst Ratings

6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 2,214.29
(+10.79% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
JPMorgan
Hold1,900.00-4.94%1,640.00Maintain07/08/2026
Axis Capital Limited
Buy2,150.00+7.57%1,875.00Maintain07/08/2026
Motilal Oswal Securities
Buy2,260.00+13.07%-New Coverage20/07/2026
JPMorgan
Hold1,640.00-17.95%1,620.00Maintain06/05/2026
JPMorgan
Hold1,620.00-18.95%1,550.00Maintain05/02/2026

Emcure Pharmaceuticals Ltd Earnings Call Summary for Q1/2027

  • Q1 FY2027 revenue rose 22.8% YoY to INR 2,580 crores; EBITDA up 25.8% to INR 508 crores; PAT climbed 36.2% to INR 292 crores.
  • International sales drove growth, up 34.2% to INR 1,485 crores; domestic revenue grew 10.2% but organic growth lagged at 6-7%.
  • EBITDA margin improved 50 bps to 19.7%; gross margin fell to 58.4% due to higher international mix, expected to settle around 59% for FY2027.
  • Management reaffirmed low-to-mid-teens revenue growth guidance for FY2027 with 70-100 bps EBITDA margin expansion; domestic growth expected to improve.
  • Net debt to rise to INR 1,450-1,560 crores in Q2 post-acquisitions before targeting net cash by end of FY2028; semaglutide filing in Canada planned.
Last Updated: 06/08/2026, 12:40
Read Full Transcript

Earnings

Latest Release
06/08/2026
EPS / Forecast
15.40 / --
Revenue / Forecast
25.8B / 23.81B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -
Dividend Yield
0.18%
Industry Median 0.66%
Annualised payout
3.60
Paid annually
5-Years Growth
-
Growth Streak

Compare EMCU to Peers and Sector

Metrics to compare
EMCU
Peers
Sector
Relationship
P/E Ratio
37.4x34.5x−0.4x
PEG Ratio
1.051.630.00
Price/Book
7.6x5.8x2.6x
Price / LTM Sales
3.9x4.9x3.1x
Upside (Analyst Target)
12.3%8.8%48.2%
Fair Value Upside
Unlock−0.9%5.8%Unlock

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.

Employees
6731
Market
India

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
15.16M8.00%30.25B
Other Institutional Investors
21.71M11.45%43.32B
Public Companies & Retail Investors
152.72M80.55%304.70B
Total
189.59M100.00%378.27B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Unity Trust7.65%14,508,00028,946,362
Bain Capital, LP3.87%7,339,45914,643,689

People Also Watch

2,812.80
RRKA
+2.03%
467.30
HONA
-2.05%
3,246.00
ACUA
-1.10%
1,706.70
NUVA
+4.35%
4,859.80
NETE
-0.88%

FAQ

What Is the Emcure Pharmaceuticals (NSE: EMCU) Share Price Today?

The Emcure Pharmaceuticals stock price today is 1,998.70 INR.

What Stock Exchange Does Emcure Pharmaceuticals (EMCU) Trade On?

Emcure Pharmaceuticals is listed and trades on the India National Stock Exchange.

What Is the Ticker (Stock Symbol) for Emcure Pharmaceuticals?

The stock symbol (also called a 'ticker') for Emcure Pharmaceuticals is "EMCU."

Does Emcure Pharmaceuticals Pay Dividends? What’s The Current EMCU Dividend Yield?

Yes, EMCU Pays Dividends to its Shareholders. The current Emcure Pharmaceuticals dividend yield is 0.18%.

What Is the Current Emcure Pharmaceuticals Market Capitalisation?

As of today, Emcure Pharmaceuticals (NSE: EMCU) market cap is 378.27B INR.

When Is the Next Emcure Pharmaceuticals Earnings Date?

Emcure Pharmaceuticals's next earnings report will be released on 05/11/2026.

Is EMCU a Buy or Sell From a Technical Analyst Perspective?

Based on today's Emcure Pharmaceuticals moving averages and other technical indicators, the daily buy/sell signal for EMCU stock is Strong Buy.

How Many Times Has Emcure Pharmaceuticals Stock Split?

Emcure Pharmaceuticals has split 0 times. (See the EMCU stock split history page for full effective split date and price information.)

How Many Employees Does Emcure Pharmaceuticals Have?

Emcure Pharmaceuticals has 6731 employees, based on their latest Companies House report.

What is the current trading status of Emcure Pharmaceuticals (NSE: EMCU)?

As of 11/08/2026, Emcure Pharmaceuticals (EMCU) is trading at a share price of 1,998.70 INR, with a previous close of 1,995.20 INR. The stock has fluctuated within a day range of 1,985.00 INR to 2,024.90 INR, while its 52-week range spans from 1,260.00 INR to 2,048.00 INR.

What Is Emcure Pharmaceuticals (EMCU) Price Target According to Analysts?

The average 12-month price target for Emcure Pharmaceuticals is 2,214.29 INR, with a high estimate of 2362 INR and a low estimate of 1900 INR. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +10.79% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.